Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept
ObjectivesTo investigate whether biomarkers related to B cell activation and autoantibody production are associated with the response to abatacept in rheumatoid arthritis (RA) patients.MethodsTwenty-five patients with RA were enrolled in this study. Responders (n=10) to abatacept were subjects who a...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1504454/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589615125495808 |
|---|---|
| author | Ting Wang Natalia V. Giltiay Christian Lood Ning Wang Bobby Kwanghoon Han |
| author_facet | Ting Wang Natalia V. Giltiay Christian Lood Ning Wang Bobby Kwanghoon Han |
| author_sort | Ting Wang |
| collection | DOAJ |
| description | ObjectivesTo investigate whether biomarkers related to B cell activation and autoantibody production are associated with the response to abatacept in rheumatoid arthritis (RA) patients.MethodsTwenty-five patients with RA were enrolled in this study. Responders (n=10) to abatacept were subjects who achieved ACR50 response at week 24. Serum levels of soluble biomarkers were measured with ProcartaPlex by Luminex or ELISA. Peripheral blood mononuclear cells were isolated and analysed for T cell and B cell subsets by flow cytometry. Patients were genotyped for human leukocyte antigen (HLA)-DRB1 shared epitope (SE) alleles. Baseline levels and longitudinal changes of markers were assessed between responders and nonresponders.ResultsBaseline levels of anti-cyclic citrullinated peptide (anti-CCP) antibodies (p=0.01), IgM rheumatoid factor (RF) (p=0.02), CXC chemokine ligand 13 (CXCL13, p=0.02), sCD23 (p<0.05), as well as frequencies of CD19+CD11c+IgD-CD27- B cells (p=0.04), were higher in responders than nonresponders. Among them, anti-CCP and frequencies of CD19+CD11c+IgD-CD27- B cells were independently associated with response to abatacept. The presence of two alleles of SE was associated with responders (p=0.04). Patients with 2 alleles of SE had higher levels of anti-CCP (p=0.02) and IgM RF (p=0.04) compared to patients with 0 or 1 allele. Further, IgM RF and CXCL13 levels decreased only in responders (p=0.02 and 0.004 respectively, at week 24), while anti-CCP levels did not decrease significantly in either responders or nonresponders.ConclusionMarkers of B cell activation including anti-CCP and frequencies of CD19+CD11c+IgD-CD27- B cells in RA were associated with response to abatacept. IgM RF and CXCL13 decreased only in responders and could be potentially used as pharmacodynamic markers. |
| format | Article |
| id | doaj-art-2f8107afdb494cac8d389e961f5865ab |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-2f8107afdb494cac8d389e961f5865ab2025-01-24T10:29:12ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.15044541504454Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abataceptTing WangNatalia V. GiltiayChristian LoodNing WangBobby Kwanghoon HanObjectivesTo investigate whether biomarkers related to B cell activation and autoantibody production are associated with the response to abatacept in rheumatoid arthritis (RA) patients.MethodsTwenty-five patients with RA were enrolled in this study. Responders (n=10) to abatacept were subjects who achieved ACR50 response at week 24. Serum levels of soluble biomarkers were measured with ProcartaPlex by Luminex or ELISA. Peripheral blood mononuclear cells were isolated and analysed for T cell and B cell subsets by flow cytometry. Patients were genotyped for human leukocyte antigen (HLA)-DRB1 shared epitope (SE) alleles. Baseline levels and longitudinal changes of markers were assessed between responders and nonresponders.ResultsBaseline levels of anti-cyclic citrullinated peptide (anti-CCP) antibodies (p=0.01), IgM rheumatoid factor (RF) (p=0.02), CXC chemokine ligand 13 (CXCL13, p=0.02), sCD23 (p<0.05), as well as frequencies of CD19+CD11c+IgD-CD27- B cells (p=0.04), were higher in responders than nonresponders. Among them, anti-CCP and frequencies of CD19+CD11c+IgD-CD27- B cells were independently associated with response to abatacept. The presence of two alleles of SE was associated with responders (p=0.04). Patients with 2 alleles of SE had higher levels of anti-CCP (p=0.02) and IgM RF (p=0.04) compared to patients with 0 or 1 allele. Further, IgM RF and CXCL13 levels decreased only in responders (p=0.02 and 0.004 respectively, at week 24), while anti-CCP levels did not decrease significantly in either responders or nonresponders.ConclusionMarkers of B cell activation including anti-CCP and frequencies of CD19+CD11c+IgD-CD27- B cells in RA were associated with response to abatacept. IgM RF and CXCL13 decreased only in responders and could be potentially used as pharmacodynamic markers.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1504454/fullabataceptpredictive biomarkerB cellCXCL13rheumatoid factorrheumatoid arthritis |
| spellingShingle | Ting Wang Natalia V. Giltiay Christian Lood Ning Wang Bobby Kwanghoon Han Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept Frontiers in Immunology abatacept predictive biomarker B cell CXCL13 rheumatoid factor rheumatoid arthritis |
| title | Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept |
| title_full | Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept |
| title_fullStr | Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept |
| title_full_unstemmed | Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept |
| title_short | Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept |
| title_sort | evaluation of b cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept |
| topic | abatacept predictive biomarker B cell CXCL13 rheumatoid factor rheumatoid arthritis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1504454/full |
| work_keys_str_mv | AT tingwang evaluationofbcellrelatedmarkersandautoantibodiesinrheumatoidarthritispatientstreatedwithabatacept AT nataliavgiltiay evaluationofbcellrelatedmarkersandautoantibodiesinrheumatoidarthritispatientstreatedwithabatacept AT christianlood evaluationofbcellrelatedmarkersandautoantibodiesinrheumatoidarthritispatientstreatedwithabatacept AT ningwang evaluationofbcellrelatedmarkersandautoantibodiesinrheumatoidarthritispatientstreatedwithabatacept AT bobbykwanghoonhan evaluationofbcellrelatedmarkersandautoantibodiesinrheumatoidarthritispatientstreatedwithabatacept |